Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone

 
• By Joseph Haas

Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.

Injection
Novavax Phase III data may position it to file seasonal flu vaccine at FDA this year

More from Clinical Trials

More from R&D